Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Darusentan Effect on PET Uptake Heterogeneity

This study has been completed.
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
K.Lance Gould, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00738049
First received: August 19, 2008
Last updated: July 25, 2014
Last verified: July 2014
  Purpose

The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after treatment with selective ETA receptor antagonist darusentan 100 mg per day for 2 weeks compared to baseline and post-treatment PET scans in clinically stable subjects with coronary atherosclerosis and/or risk factors.


Condition Intervention Phase
Coronary Artery Disease
Endothelial Dysfunction
Drug: darusentan 100 mg
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Change During Darusentan Treatment in the Markovian Homogeneity Number, a Value That Quantitates Myocardial Perfusion Heterogeneity [ Time Frame: 0, 2, 4, and 6 weeks ] [ Designated as safety issue: No ]
    Markovian homogeneity analysis characterizes an image produced by a PET scan by examining the probability that a pixel with a given intensity will have a neighbor with a different intensity. The homogeneity index ranges from >0 to 1, where a value near 0 represents an image with a high probability that neighboring pixels have intensity values that differ greatly, and a value near 1 represents an image with a high probability that neighboring pixels have similar intensity values.


Secondary Outcome Measures:
  • Change During Darusentan Treatment in Absolute Flow at Rest and Hyperemia [ Time Frame: 0, 2, 4, and 6 weeks ] [ Designated as safety issue: No ]
  • Change During Darusentan Treatment in the Coronary Flow Reserve (CFR) [ Time Frame: 0, 2, 4, and 6 weeks ] [ Designated as safety issue: No ]
    CFR is calculated as the unitless ratio between hyperemic to resting flow


Enrollment: 40
Study Start Date: June 2009
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group 1
Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
Drug: darusentan 100 mg
All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
Other Names:
  • darusentan
  • CID 177236
  • LU-135252
  • HMR-4005
  • 171714-84-4
Active Comparator: Group 2
Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
Drug: darusentan 100 mg
All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
Other Names:
  • darusentan
  • CID 177236
  • LU-135252
  • HMR-4005
  • 171714-84-4

Detailed Description:

This 6-week, Phase 2, randomized, double-blind, crossover, investigator-initiated, single-center study will determine the feasibility of detecting the effect of darusentan 100 mg once daily on the extent of myocardial perfusion heterogeneity in subjects with documented CAD, as measured by cardiac PET imaging. Prior to the initiation of any study procedures, an Informed Consent Form and HIPAA Authorization will be reviewed and signed by each subject. Screening assessments and evaluations may be conducted over a period of not more than 4 weeks.

Following a baseline PET scan (PET 1) subjects will be randomized to one of two treatment groups (Group 1 or Group 2), and receive blinded treatment for a total of 4 weeks. The 4-week treatment period will have two phases, Phase 1 and Phase 2. Group 1 will receive darusentan 100 mg for 2 weeks during Phase 1, then placebo for 2 weeks during Phase 2. Group 2 will receive placebo for 2 weeks during Phase 1, then darusentan 100 mg for 2 weeks during Phase 2. Following 4 weeks of treatment with blinded study drug, subjects in both treatment groups will be withdrawn from study drug for an additional 2 weeks. Maximum darusentan exposure in this study will be 2 weeks, and maximum placebo exposure in this study will be 2 weeks. Adjustments to the number or dosage of concomitant medications required for study entry will not be permitted at any time during the study.

A physical exam will be done at baseline and week 6 as well as blood chemistry and hematology samples taken. Vital signs and any adverse events will be monitored at each visit.

Efficacy will be assessed through cardiac PET imaging. In total, four PET scans will be administered: the first at the Randomization Visit (PET 1, Week 0); the second at the conclusion of Phase 1 (PET 2, Week 2); the third at the conclusion of Phase 2 (PET 3, Week 4) and the fourth at the conclusion of the Withdrawal period (PET 4, Week 6).

Subjects will be instructed to take their study drug with or without food once daily at approximately the same time in the morning throughout the course of the study. Subjects will also be instructed to take all concomitant medications consistently and at the same time each day throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must be competent to provide written informed consent. Subjects must sign an IRB approved ICF and HIPAA Authorization prior to the initiation of any study procedures. All men must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking study drug, and queried regarding their understanding of the potential risks as described in the ICF.
  2. Subjects must be greater than 18 years of age.
  3. Female subjects must be surgically sterile or documented as post-menopausal for at least 2 years.
  4. Subjects must have documented coronary artery disease as evidenced by previous myocardial infarction, interventional procedure, significant stenosis by cardiac catheterization, or an abnormal perfusion study.
  5. Subjects must have an abnormal PET scan.

Exclusion Criteria:

  1. Subjects with acute heart failure
  2. Subjects with sustained or symptomatic hypotension (SBP 90 mmHg)
  3. Subjects with uncontrolled hypertension (SBP of 170 mmHg or DBP of 100 mmHg) at Screening
  4. Subjects with unstable angina pectoris
  5. Subjects with acute myocardial infarction, stroke, transient ischemic attack, or coronary angioplasty within the last 6 months
  6. Subjects with primary valvular disease
  7. Subjects with significant vascular aneurysm
  8. Subjects with a documented history of renal failure
  9. Subjects with liver disease (total bilirubin 3 mg/dL or serum ALT or AST >2X ULN)
  10. Subjects with active malignancy
  11. Subjects with a fatal non-cardiovascular disease that they are expected to succumb to within 1 year
  12. Female subjects that are pregnant or lactating
  13. Female subjects with the potential for child-bearing
  14. Female subjects being treated with hormone therapies
  15. Subjects with uncontrolled diabetes mellitus
  16. Subjects with diabetes with gastro paresis or severe neuropathy
  17. Subjects with a history of substance abuse within the last 2 years
  18. Subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the Screening Visit
  19. Subjects with known hypersensitivity or allergy to L-arginine, aminophylline, adenosine, or dipyridamole
  20. Subjects who have a planned surgical procedure during the course of the study
  21. Subjects taking herbal food supplements (L-carnitine, L-arginine or Ginko biloba)
  22. Subjects with known active or dormant type 2 herpes simplex virus infections
  23. Subjects with a contraindication to treatment with an ERA. Contraindications may include, but are not limited to, evidence of elevated liver function tests (e.g., aminotransferases >2X ULN) or an event defined as a serious adverse event attributed to previous treatment with an ERA
  24. Subjects who are judged by the investigator to be ineligible for this study for any other reason
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00738049

Locations
United States, Texas
Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
K.Lance Gould
Gilead Sciences
Investigators
Principal Investigator: K Lance Gould, MD University of Texas Medical School at Houston
Principal Investigator: Nils Johnson, MD University of Texas Medical School at Houston
  More Information

Publications:

Responsible Party: K.Lance Gould, Martin Bucksbaum distinguished University chair, Professor of Cardiovascualr MEdicine and Executive Director, Weatherhead P.E.T. Center for Preventing and Reversing Atherosclerosis, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00738049     History of Changes
Other Study ID Numbers: HSC-MS-08-0380
Study First Received: August 19, 2008
Results First Received: January 25, 2013
Last Updated: July 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by The University of Texas Health Science Center, Houston:
atherosclerosis
coronary artery disease
myocardial perfusion defect
endothelial dysfunction
endothelin receptor blockade

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014